Niagen Bioscience (NASDAQ:NAGE) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Niagen Bioscience (NASDAQ:NAGE) posted its quarterly earnings results on Tuesday. The company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.02 by $0.03, Zacks reports. Niagen Bioscience had a return on equity of 23.12% and a net margin of 15.24%.

Niagen Bioscience Trading Down 3.9%

Shares of Niagen Bioscience stock traded down $0.28 during trading hours on Tuesday, hitting $6.95. 1,078,639 shares of the company were exchanged, compared to its average volume of 975,393. Niagen Bioscience has a 1 year low of $5.16 and a 1 year high of $14.69. The business has a 50-day moving average of $8.54 and a 200-day moving average of $9.71. The stock has a market capitalization of $554.28 million, a price-to-earnings ratio of 33.10 and a beta of 2.13.

Analyst Upgrades and Downgrades

Several research analysts recently commented on NAGE shares. Wall Street Zen cut Niagen Bioscience from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 9th. HC Wainwright boosted their price objective on Niagen Bioscience from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Monday, August 11th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Niagen Bioscience in a research report on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $13.42.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.